Transformative
Liver Disease Diagnostics.

Livivos is Introducing the Only Accurate Point-of-Care Liver Disease Diagnostic Device

Global Epidemic.

“An estimated 80 million to 100 million Americans have nonalcoholic fatty liver disease, which causes the liver to swell with dangerous levels of fat. Fatty liver disease typically has few symptoms, and many people who have it don’t know it.”

The New York Times – To Fight Fatty Liver, Avoid Sugary Foods and Drinks. 

Problem.

“Signs of the disease are asymptomatic, so a person often is not diagnosed with NASH until it advances to a late stage, when cirrhosis begins to ravage the body”.

CNBC – The $35 billion race to cure a silent killer that affects 30 million Americans. 

Need.

“The diagnosis of NASH can be difficult, as most patients in early stages of the disease have no symptoms. The identification of patients is currently not possible by a typical physical examination.”

The Wall Street Journal – A Big, Fatty Opportunity for Big Pharma. 

Play Video

“The diagnosis of NASH can be difficult, as most patients in early stages of the disease have no symptoms. The identification of patients is currently not possible by a typical physical examination.”

“Signs of the disease are asymptomatic, so a person often is not diagnosed with NASH until it advances to a late stage, when cirrhosis begins to ravage the body”.

The Need for Effective Diagnosis.

Liver Disease Prevalence

Prevalence

NAFLD can progress to NASH (Non-alcoholic Steatohepatitis) accompanied by advanced fibrosis, affecting approximately 3% of the global population. Alarmingly, liver disease claims the lives of 1.75 million individuals annually. 

NAFLD is associated with prevalent health conditions worldwide, including cardiovascular disease, cancer, and diabetes. 

Economic Burden

Economic Burden

Current NAFLD trends indicate that the disease will soon be the leading cause of liver transplant. There has been a rapid increase in the number of drugs targeting this disease that are undergoing clinical trial. The critical prevalence of fatty liver disease comes with an associated annual direct medical cost of over $100 billion, in the United States alone, with a significantly higher burden when societal costs are included.

Preventive Medicine

Preventive Medicine

The diagnosis of liver disease faces obstacles due to the constraints of conventional diagnostic techniques. It is imperative to have a precise and widely accessible testing approach in order to combat the escalating prevalence of this disease. Livivos presents a viable solution by offering quantitative results in point-of-care settings. With the introduction of LiverScope®, there is now a promising opportunity to reverse the upward trajectory of liver disease.

Liver Disease Prevalence.

The global epidemic of fatty liver disease has reached unprecedented levels, growing at an alarming rate, presenting a major challenge for public health.

There is a critical need for reliable and easily accessed liver disease diagnosis. Yet, no accurate point-of-care testing is currently available in the diagnostic market.

Learn more

Improved Diagnostics.

LiverScope® provides instant, accurate results, without the need for image interpretation or histological examination – overcoming critical deficiencies of standard diagnostic modalities.

Livivos’s technology transforms liver disease diagnostics, responding to a fast-growing demand for effective and broadly available testing. LiverScope® will significantly advance liver testing on a larger scale and will support accurate evaluation of the response to treatments.

Learn more
liversope

Clinical Markets Benefiting from Effective Liver Disease Diagnostics.

Point-of-Care Diagnosis

Point-of-Care Diagnosis

Preventive medicine, clinical triage for the millions of patients with suspected NAFLD, and accurate long-term treatment monitoring.

Evaluating Drug Efficacy

Evaluating Drug Efficacy

Supporting regulatory clinical trials. There is a rapid increase in the number of liver disease drugs undergoing FDA evaluation. Livivos’s technology provides biomarkers to quantify the evolution of steatosis.

doctor

Long Term Evaluation

Monitoring of drug effectiveness after drug approval – especially for NASH drugs with anti-steatotic mechanisms of action – as they enter the clinical market.